Keyword: Ultibro Breezhaler
The COPD market is growing more and more competitive in Europe, so Novartis is looking to new heart data to give contender Ultibro an edge.
Novartis has new data in hand that could help it snatch patients from GlaxoSmithKline with Advair rival Ultibro.
Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.
Novartis has some new data it's hoping can help it weasel market share away from GlaxoSmithKline.